A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multiple-Dose Study to Evaluate the Effects of Patiromer in Heart Failure Patients

Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multiple-Dose Study to Evaluate the Effects of Patiromer in Heart Failure Patients

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2016

At a glance

  • Drugs Patiromer (Primary)
  • Indications Hyperkalaemia
  • Focus Therapeutic Use
  • Acronyms PEARL-HF
  • Sponsors Relypsa
  • Most Recent Events

    • 23 May 2012 Additional lead trial investigator (Yuri Stasiv) identified as reported by ClinicalTrials.gov.
    • 14 Apr 2012 Planned number of patients 270 added as reported by European Clinical Trials Database.
    • 16 Sep 2010 Primary endpoint 'Potassium levels' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top